PRR agonists |
|
Vaxjo ID |
387 |
|
Vaccine Adjuvant Name |
PRR agonists |
|
Alternative Names |
PRR agonists may include various specific compounds, such as TLR (Toll-Like Receptor) agonists, including MPLA (monophosphoryl lipid A), CpG-ODN (CpG oligodeoxynucleotides), and others. |
|
Adjuvant VO ID |
VO_0005669
|
|
Description |
PRR agonists are molecules that activate pattern recognition receptors in the immune system, leading to enhanced immune responses. They are used as adjuvants in vaccines to improve immunogenicity. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
pathogen-associated molecular patterns (PAMPs) and damage-associate molecular patterns (DAMPs) |
|
Structure |
The specific structures of PRR agonists vary widely depending on the agonist. For example, TLR agonists have distinct molecular structures that correspond to their receptor targets. |
|
Preparation |
PRR agonists can be derived from natural sources or synthesized. The preparation methods vary based on the specific agonist. |
|
Function |
Pathogens comprise a diverse set of immunostimulatory molecules that activate the innate immune system during infection. |
|
Safety |
The safety profiles of PRR agonists can vary; some have been shown to have favorable safety profiles in clinical applications, while others may have associated risks. The article emphasizes the need for improved safety profiles in new adjuvants. |
| References |
Tom et al., 2019: Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in biotechnology. 2019; 37(4); 373-388. [PubMed: 30470547].
|
